CELZ · Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings Inc (CELZ)
What's happening
- CELZ is up 3.33% today, trading at $0.78. — Live quote
- It's trading within 3% of its 52-week low ($0.62). (Finnhub fundamentals)
- Volume today (285) is well below its 3-month average of 7,065,900. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.41 actual vs. $-0.40 estimated (-3.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $5.2M | $7.6M | $8.5M | $7.0M | $4.3M |
| P/E | -0.97 | -1.38 | -1.66 | -1.27 | -0.81 |
| Price/Sales | — | 2539.00 | 2840.93 | 633.00 | 389.34 |
| Price/Book | 0.60 | 1.25 | 1.52 | 1.02 | 0.53 |
| EV/Revenue | — | 2539.00 | 2840.93 | 633.00 | 389.34 |
| ROE | -62.23% | -90.23% | -92.06% | -80.11% | -65.47% |
| ROA | -57.44% | -85.59% | -87.95% | -76.98% | -63.22% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-25; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -48.1% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -58762.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -79.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CELZ
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $3.0K | $0 | $8.0K | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $1.8K | $0 | $4.8K | $0 |
| Operating income | -$1.6M | -$1.5M | -$1.3M | -$1.3M | -$1.7M | -$1.1M | -$1.6M | -$1.1M |
| Net income | -$1.5M | -$1.4M | -$1.2M | -$1.2M | -$1.6M | -$1.0M | -$1.6M | -$1.0M |
| EPS (diluted) | $-0.41 | $-0.38 | $-0.48 | $-0.48 | $-0.83 | $-0.75 | $-1.11 | $0.73 |
| EPS (basic) | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -$55.3K | — | -$20.3K | — |
| Net margin | — | — | — | — | -$54.6K | — | -$19.5K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $9.4M | $6.4M | $7.8M | $5.9M | $7.1M | $8.3M | $6.7M | $6.9M |
| Total liabilities | $698.6K | $307.6K | $284.9K | $261.4K | $277.6K | $286.4K | $327.6K | $330.9K |
| Stockholders' equity | $8.7M | $6.1M | $7.5M | $5.6M | $6.8M | $8.1M | $6.3M | $6.6M |
| Total current assets | $9.0M | $6.1M | $7.4M | $5.4M | $6.6M | $7.8M | $6.1M | $6.3M |
| Total current liabilities | $698.6K | $307.6K | $284.9K | $261.4K | $277.6K | $286.4K | $327.6K | $330.9K |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | $125.0K | $125.0K | $0 | $994 | $994 | $994 | $2.2K | $3.4K |
| Intangible assets | $355.5K | $378.4K | $407.2K | $438.2K | $469.2K | $500.0K | $530.6K | $553.2K |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $684.4K | $293.5K | $270.7K | $247.2K | $263.4K | $272.2K | $273.5K | $273.8K |
| Accrued liabilities | — | — | $0 | $0 | $0 | $0 | $39.9K | $42.9K |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $6.5K | $3.1K | $3.1K | $2.6K | $2.6K | $2.6K | $1.7K | $1.4K |
| Retained earnings | -$73.5M | -$72.0M | -$70.6M | -$68.7M | -$67.5M | -$66.2M | -$64.6M | -$62.7M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.5M | -$1.3M | -$1.9M | -$1.2M | -$1.2M | -$1.6M | -$1.9M | -$985.6K |
| Investing cash flow | $0 | -$175.0K | -$50.5K | $0 | $0 | $0 | $0 | -$200.0K |
| Financing cash flow | $4.5M | $13.4K | $3.8M | $0 | $0 | $3.4M | $1.6M | -$25.4K |
| Share-based compensation | $0 | $0 | $0 | $0 | $0 | $3.5K | $27.5K | $9.2K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | $0 | $0 | -$994 | $0 | $0 | -$1.2K | -$1.2K | $0 |
| Change in accounts payable | -$16.2K | $22.8K | $23.5K | -$16.3K | -$8.7K | -$1.3K | -$364 | -$48.4K |
| Purchases of investments | $0 | $125.0K | — | — | $0 | $0 | $0 | $0 |
| Share repurchases | $0 | $0 | $0 | $0 | $0 | $10.0K | $0 | $25.4K |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $6.0K | $11.0K | $9.0K | $88.6K | $87.8K |
| Gross profit | $3.8K | $6.6K | $5.4K | $60.1K | $39.8K |
| Operating income | -$6.1M | -$5.7M | -$5.6M | -$10.2M | -$3.1M |
| Net income | -$6.0M | -$5.5M | -$5.3M | -$10.1M | $19.2M |
| EPS (diluted) | $-2.52 | $-3.71 | $-3.76 | $-0.93 | $5.61 |
| EPS (basic) | — | — | — | $-0.93 | $7.37 |
| Operating margin | -$102.4K | -$52.2K | -$62.4K | -$11.6K | -$3.6K |
| Net margin | -$99.9K | -$49.9K | -$58.7K | -$11.4K | $21.9K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $7.8M | $6.7M | $10.7M | $19.2M | $11.3M |
| Total liabilities | $284.9K | $327.6K | $371.4K | $3.3M | $1.1M |
| Stockholders' equity | $7.5M | $6.3M | $10.3M | $15.9M | $10.2M |
| Total current assets | $7.4M | $6.1M | $10.3M | $18.7M | $10.7M |
| Total current liabilities | $284.9K | $327.6K | $371.4K | $3.3M | $1.1M |
| Cash & equivalents | — | — | — | — | $10.7M |
| Accounts receivable | — | — | — | $0 | $2.5K |
| Inventory | $0 | $2.2K | $6.6K | $10.2K | $10.9K |
| Intangible assets | $407.2K | $530.6K | $441.0K | $435.6K | $527.7K |
| Accounts payable | $270.7K | $273.5K | $317.3K | $3.3M | $761.9K |
| Accrued liabilities | $0 | $39.9K | $39.9K | $39.9K | $24.4K |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $3.1K | $1.7K | $1.4K | $1.4K | $6.3K |
| Retained earnings | -$70.6M | -$64.6M | -$59.1M | -$53.8M | -$43.7M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$5.3M | -$8.0M | -$7.8M | -$2.2M |
| Investing cash flow | -$50.5K | $6.3M | $3.4M | -$10.1M | $0 |
| Financing cash flow | $7.2M | $1.5M | -$271.0K | $15.5M | $12.8M |
| Share-based compensation | $3.5K | $36.6K | $36.6K | $68.7K | $595.4K |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts receivable | — | — | $0 | -$2.5K | $2.5K |
| Change in inventory | -$2.2K | -$4.4K | -$3.6K | -$672 | $10.9K |
| Change in accounts payable | -$2.8K | -$43.9K | -$3.0M | $2.5M | $411.0K |
| Purchases of investments | — | $0 | $22.9M | $10.1M | — |
| Share repurchases | $10.0K | $175.0K | $271.0K | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CELZ as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2020-06-03 to 2026-09-24-05:00
Recent transactions
- Most recent: Warbington Timothy (President & CEO) — Grant / award of 1,000,000 shares on 2026-09-24-05:00.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Warbington Timothy | President & CEO | Grant / award | 2026-09-24-05:00 | 1,000,000 |
| Finger Michael H. | Reporting person | Open market sale | 2025-02-19-05:00 | 750 |
| Ichim Thomas | Reporting person | Open market sale | 2021-07-22-05:00 | 1,450,000 |
| CREATIVE MEDICAL HEALTH INC. | Reporting person | Other acquisition/disposition | 2021-01-08-05:00 | 44,642,857 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-24-05:00 | Warbington Timothy | President & CEO | Grant / award | 1,000,000 | — |
| 2025-02-19-05:00 | Finger Michael H. | Reporting person | Open market sale | 750 | $5.75 |
| 2025-02-18-05:00 | Finger Michael H. | Reporting person | Open market sale | 750 | $5.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 00:40 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-25 | 8-K | 2026-09-24 | View on SEC.gov → |
| 2026-08-31 | 8-K | 2026-08-28 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-30 | View on SEC.gov → |
| 2026-05-08 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-03-20 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2025-12-31 | 8-K | 2025-12-26 | View on SEC.gov → |
| 2025-12-19 | 8-K | 2025-12-18 | View on SEC.gov → |
| 2025-11-12 | 8-K | 2025-11-06 | View on SEC.gov → |
| 2025-11-07 | 10-Q | 2025-09-30 | View on SEC.gov → |
| 2025-10-31 | 8-K | 2025-10-29 | View on SEC.gov → |
Recent news
Headlines about CELZ (Creative Medical Technology Holdings, Inc.). Links open the publisher — we don’t host full articles.
-
Creative Medical Technology Holdings Highlights Positive Ultrasome™ Pilot Data in Knee Osteoarthritis Study
Quiver Quantitative · 2026-10-20 -
Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
Yahoo · 2026-10-20 -
Creative Medical Technology Highlights Ultrasome Data Showing 93% Response Rate, 65% Pain Reduction In Knee Osteoarthritis Study
Benzinga · 2026-10-20 -
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
Yahoo Finance · 2026-09-17 -
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
Yahoo Finance · 2026-08-20 -
Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy
Yahoo Finance · 2026-08-06 -
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Yahoo Finance · 2026-08-06 -
Creative Medical Technology Holdings Issues Mid-Year Update
Yahoo Finance · 2026-07-01
No headlines in this category right now — try “All”.